Spiroveloergometry role in risk assessment of patients with idiopathic pulmonary hypertension: clinical case of successful treatment with riociguat
Abstract
According to the recommendations of the European society of cardiology and the European respiratory society on the diagnosis and treatment of pulmonary hypertension (2015) spiroveloergometry parameters (peak oxygen consumption and ventilation equivalent of carbon dioxide) are important components of the scale of risk stratification of mortality in patients with pulmonary arterial hypertension. The obtained results as a complement to clinical and hemodynamic parameters played an important role in the further tactics of patient management, timely escalation of specific therapy of pulmonary arterial hypertension, which is the key to a stable course of the disease.
About the Authors
Z. S. Valieva
Research Institute for Clinical Cardiology n.a. A. L. Myasnikov of Russian Cardiological Research and Production Complex
Russian Federation
Russian Federation
I. N. Taran
Research Institute for Clinical Cardiology n.a. A. L. Myasnikov of Russian Cardiological Research and Production Complex
Russian Federation
Russian Federation
T. V. Martynyuk
Research Institute for Clinical Cardiology n.a. A. L. Myasnikov of Russian Cardiological Research and Production Complex
Russian Federation
Russian Federation
I. E. Chazova
Research Institute for Clinical Cardiology n.a. A. L. Myasnikov of Russian Cardiological Research and Production Complex
Russian Federation
Russian Federation
References
1. Galie' N, HumbertM, Vachiery J-L, Gibbs JS, Lang I, Torbicki A, Simonneau G, Peacock A, VOnkNoordegraaf A, Beghetti M, Ghofrani A, Gomez-Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci-Cerinic M, McDonagh T, Pierard L, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016;37: 67-124.
2. Чазова И. Е., Мартынюк Т. В., Наконечников С. Н. Итоги Европейского конгресса кардиологов 2015 года: новая версия рекомендаций по диагностике и лечению легочной гипертензии. Евразийский кардиологический журнал 2015; 4: 3-10.
3. Полтавская М. Г., Мкртумян Э. А., Свет А. В., Долецкий А. А., Новикова Н. А., Гилярова М. Ю. Нагрузочные пробы с газовым анализом: пособие для врачей общей практики. Москва, 2009; 2-25.
4. Deboeck G, Scoditti C, Huez S, et al. Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension. Eur Respir J 2012; 40: 1410-1419.
5. Sun XG, Hansen JE, Oudiz RJ, et al. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001; 104: 429-435.
6. McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension. J Am CollCardiol 2013; 62: Suppl. 25, D 73-D 81.
7. Таран И. Н., Валиева З.С, Мартынюк Т. В., Наконечников С. Н., Чазова И. Е. Вклад спировелоэргометрии в диагностический алгоритм обследования больных с легочной артериальной гипертензией. Медицинский алфавит № 30 / 2016, том № 3, Больница - все для ЛПУ, ст. 19-25.
8. Мартынюк Т. В., Чазова И. Е. Стратегия медикаментозного лечения легочной артериальной гипертензии в свете современных зарубежных рекомендаций. Системные гипертензии № 2, том 13, 2016, с. 46-64.
9. Darren B. Taichman et al. Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults. CHEST Guideline and Expert Panel Report. CHEST2014; 146 (2): 449-475.
Review
For citations:
Valieva Z.S., Taran I.N., Martynyuk T.V., Chazova I.E. Spiroveloergometry role in risk assessment of patients with idiopathic pulmonary hypertension: clinical case of successful treatment with riociguat. Medical alphabet. 2017;1(4):25-30. (In Russ.)
Views:
323
Email this article 